Fineron 10 mg (Tablet)
Unit Price: ৳ 80.00 (1 x 10: ৳ 800.00)
Strip Price: ৳ 800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Everest pharmaceuticals ltd |
Indications
- Reduce risk of sustained eGFR decline
- Reduce risk of end-stage kidney disease
- Reduce risk of cardiovascular death
- Reduce risk of nonfatal myocardial infarction
- Reduce risk of hospitalization for heart failure
- For adult patients with chronic kidney disease associated with type 2 diabetes
Pharmacology
- Nonsteroidal
- Selective antagonist of the mineralocorticoid receptor (MR)
- Blocks MR mediated sodium reabsorption
- Blocks MR overactivation in epithelial and nonepithelial tissues
- Contributes to fibrosis and inflammation
- High potency and selectivity for the MR
- No relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
- Mean systolic blood pressure decrease
- Mean diastolic blood pressure decrease
- Complete absorption after oral administration
- Metabolism resulting in absolute bioavailability of 44%
- Cmax achieved between 0.5 and 1.25 hours after dosing
- Exposure increased proportionally over a dose range
- Steady state achieved after 2 days of dosing
- Plasma protein binding of finerenone is 92%
- Primary metabolism by CYP3A4
Dosage & Administration
- Recommended starting dosage of 10 mg or 20 mg orally once daily
- Increase dosage to target dose of 20 mg once daily after 4 weeks
- Tablets may be taken with or without food
- Different starting doses based on eGFR levels
- Option for patients who are unable to swallow whole tablets
- Target daily dose of 20 mg
- Monitoring serum potassium levels
- Adjusting dose based on serum potassium levels
- Guidance for missed doses
Interaction
- Contraindication with strong CYP3A4 inhibitors
- Avoid concomitant intake of grapefruit or grapefruit juice
- Monitor serum potassium during concomitant use with moderate or weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- Contraindicated in concomitant use with strong CYP3A4 inhibitors
- Contraindicated in patients with adrenal insufficiency
Side Effects
- Hyperkalemia
- Hypotension
- Hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- Animal studies showing developmental toxicity
- No data on presence in human milk
- Avoid breastfeeding during treatment and for 1 day after treatment
Precautions & Warnings
- Risk for developing hyperkalemia
- Importance of measuring serum potassium and eGFR before initiation of treatment
- Do not initiate if serum potassium is > 5.0 mEq/L
- Need for periodic serum potassium monitoring
- Considerations for patients at risk for hyperkalemia
Use in Special Populations
- Safety and efficacy not established in patients below 18 years of age
- No overall differences in safety or efficacy observed in geriatric population
- No dose adjustment required for geriatric patients
- Avoid use in patients with severe hepatic impairment (Child Pugh C)
- Considerations for patients with mild or moderate hepatic impairment
Overdose Effects
- Immediate interruption of treatment in case of suspected overdose
- Likely manifestation of overdose is hyperkalemia
- Standard treatment for hyperkalemia
- Unlikely efficient removal by hemodialysis
Therapeutic Class
- Mineralocorticoid Receptor Antagonists
Storage Conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children